

Addressing Unmet Needs in Corneal and Anterior Segment Diseases

A differentiated therapeutic approach targeting high-value, underserved rare ocular diseases

Corporate Highlights | Q1 2026



Nasdaq: OKYO

Disclaimer

By accepting and using this presentation, you will be deemed to agree not to disclose any information contained herein except as may be required by law. Additionally, certain information contained in this presentation has been obtained from published sources prepared by other parties, which in certain cases have not been updated to the date hereof. While such information is believed to be reliable for the purpose used in this presentation, each of OKYO Pharma Limited ("OKYO") and their respective related parties do not assume any responsibility for the accuracy or completeness of such information, and which has not been independently verified by OKYO or its related parties. Except where otherwise indicated herein, the information provided in this presentation is based on matters as they exist as of the date of preparation and not as of any future date and will not be updated or otherwise revised to reflect information that subsequently becomes available, or circumstances existing or changes occurring after the date of this presentation.

Certain information contained in this presentation constitutes "forward-looking statements," which can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue," "target", "aim", "forecast", "plan" or "believe" (or the negatives thereof) or other variations thereon or comparable terminology. These forward-looking statements are statements regarding OKYO's intentions, beliefs or current expectations concerning, inter alia, OKYO or its group's results of operations, financial condition, liquidity, prospects, growth, strategies and the industry in which OKYO and its group operates, and include statements regarding OKYO's planned pre-clinical studies and clinical trials, regulatory approval process, and demand for OKYO's product candidates are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those suggested by such forward-looking statements. These factors include, but are not limited to, the following: OKYO has incurred significant net losses and anticipates that it will continue to incur significant net losses for the foreseeable future; OKYO has never generated any revenue from product sales and may never be profitable, OKYO will need to raise additional funding in the future, which may not be available on acceptable terms, or at all, OKYO may not be able to obtain exclusivity or intellectual property rights for its product candidates or prevent others from developing similar competitive products. Other risks and uncertainties affecting OKYO are described in the "Risk Factors" section and in other sections included in OKYO's Annual Report on Form 20-F and Reports on Form 6-K filed with the SEC. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of OKYO to be materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond OKYO's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators and other factors such as OKYO's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which OKYO operates or in economic or technological trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. OKYO expressly disclaims any obligation or undertaking to release any updates or revisions to these forward-looking statements to reflect any change in OKYO's expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based after the date of this presentation or to update or to keep current any other information contained in this presentation. No representation or warranty is made as to the achievement or reasonableness of and no reliance should be placed on such forward-looking statements. There is no guarantee that OKYO will generate a particular rate of return. In addition, prior to making any investment decision prospective investors should carefully consider the risk factors described in the Registration Statement. Accordingly, investors should not rely on such forward-looking statements in this presentation.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any of OKYO's securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration of qualification under the securities laws of any such state or other jurisdiction.

Ophthalmic Leadership Bridging Scientific Innovation and Value-Creation

Management Team



Robert J. Dempsey
Chief Executive
Officer/Director

30+ years domestic and global ophthalmic commercial leadership and deep ocular surface experience leading the divestiture of Xiidra® to Novartis in 2019 including \$3.4 billion upfront and up to an additional \$1.9 billion in potential milestone payments and launching Restasis®



Gary Jacob, Ph.D.
Chief Development
Officer/Director

35+ years pharmaceutical and biotechnology experience across research and development, operations, business development, and capital financing activities; owns over 30 patents and is the co-inventor of two FDA approved pharmaceutical drugs



Raj Patil, Ph.D.
Chief Scientific
Officer

30+ years of domestic and global ophthalmic experience combining academic scholarship excellence; deep pharmaceutical R&D experience with extensive anterior and posterior segment research experience



Keeren Shah
Chief Financial
Officer

20+ years of finance and accounting leadership across biotech and multiple sectors, spanning operational strategy, capital formation, cash management, regulatory compliance, investor relations, and M&A support

Scientific Advisory Board



Pedram Hamrah, MD



Jay S. Pepose, MD, Ph. D.



Victor Perez, MD



Anat Galor, MD




Mark Milner, MD



Mina Massaro-Giordano, MD



Pioneering a New Ocular Therapeutic Market with No Approved Options



Urcosimod (0.05%)
(formally OK-101)

- Novel, non-opioid, dual anti-inflammatory and pain-relieving, preservative-free therapy for neuropathic corneal pain (NCP)
- A potentially promising candidate for the treatment of both inflammation and pain on the ocular surface



Neuropathic Corneal Pain

- Severe, debilitating condition, significantly under-researched disease with **NO FDA-approved drug**
- Patients commonly experience pain, photophobia, burning and foreign body sensation



Novel MOA

- Urcosimod targets the ChemR23 receptor, a differentiated dual mechanism that modulates both immune-mediated inflammation and neuropathic pain signaling



Clinical Proof of Concept (POC)

- Urcosimod (0.05%) demonstrated **clinically meaningful** pain reduction
- 5.5-point improvement on a 10-point VAS (vs. ~2.75 for placebo)
 - 75% of patients achieved >80% pain improvement
 - Signaled corneal nerve restoration



Safety

- Favorable safety and tolerability profile, including no serious adverse events



Development Plan

- **Phase 2b/3** NCP trial in ~150 subjects designed to meet pivotal requirements
- Topline data expected 1H2027



FDA Alignment

- Urcosimod is the **first IND granted and awarded fast track designation by FDA** to treat patients with NCP
- FDA confirmed Phase 2b/3 clinical design, including primary endpoint, sample size and development approach
- Authorized Compassionate Use of Urcosimod for Treatment of Neuropathic Corneal Pain
- Pursuing orphan drug designation strategy



Intellectual Property

- Strong IP protection until 2039

OKYO Development Pipeline





Market Overview

NCP: A Significantly Under-Researched Disease with Substantial Impact on Patient Quality of Life

Disease Background^{1,2,3,4,5,6}

- Neuropathic corneal pain (NCP) is **an ill-defined disease** that causes eyes, face, or head **sensitivity and pain**, often in response to a non-painful stimuli
- Severe, debilitating pain can impact **patient quality of life and ability to work**
- NCP is **challenging to diagnose**, with **diagnosis often by exclusion** and with consideration of history, symptoms, physical examination & imaging findings
- **Misdiagnosis as Dry Eye Disease (DED)** is common due to likeness of symptoms, delaying treatment and relief from pain

NCP is an Underserved Market

- There is presently no FDA-approved drug to treat NCP
- Often underdiagnosed, as the symptoms can overlap with other eye conditions, and treatment can be difficult to manage effectively
- Current treatments are limited to short term NSAIDs, steroids, and opioids in severe cases. Side effects and the risk of addiction to opioids is a serious concern


Symptoms¹

Light / air sensitivity
Foreign body sensation
Burning
Severe eye dryness



Characteristics of Neuropathic Corneal Pain (NCP)	
Definition	Neuropathic pain from corneal nerve dysfunction
Mechanism	Peripheral ± central sensitization
Clinical Signs	Minimal signs despite severe pain
Pain Quality	Burning, electric, stabbing, allodynia
Triggers	Light, wind, touch
Response to Eye Meds	Poor or incomplete response
Diagnosis Type	Specific mechanistic diagnosis
Treatment	Neuromodulators, serum tears, nerve repair
Relationship	Subset of chronic eye pain

NCP Patient Journey



Patients are commonly **misdiagnosed** before being referred to more specialized eyecare professional **delaying treatment and worsening symptoms**

Physicians frustrated with lack of **effective diagnostic tools and clear criteria** leading to **delayed diagnosis, underdiagnosis, and misdiagnosis**

Delayed diagnosis results in patients progressing into **centralized pain** which is harder to treat

Rising Scrutiny of Gabapentin Highlights Need for Earlier, Targeted NCP Diagnosis

Wall Street Journal: “The Hidden Risks of America’s Most Popular Prescription Painkiller”

- Gabapentin increasingly prescribed off-label for chronic pain, despite mixed efficacy
- 8 states have reclassified gabapentin schedule V controlled substance; 12 additional states require stricter reporting on use
- Growing concerns around dependence, misuse, and masking underlying disease
- Reliance on systemic pain masking underscores the lack of approved, disease-directed therapies for NCP



December 24, 2025



Mechanism of Action & Clinical Rationale

Urcosimod: A Lipid-Conjugated Chemerin Peptide

- **First-in-Class chemerin receptor agonist** that modulates neuro-immune cross-talk
- **Dual mechanism of action:** targets both immune cell-mediated inflammation and neuronal/glial cell populations in the dorsal root ganglion
- **Topically active peptide** designed for enhanced potency and corneal retention
- **Preservative-free, EDTA-free, and isotonic formulation**, optimized for sensitive eyes and chronic use

Targeting ChemR23 (CMKLR1 GPCR Receptor)


Modulates
Inflammation pain

Receptor localization

Expressed on immune and neuronal cells, linking inflammation and pain signaling.

Endogenous ligand

Chemerin: 136 aa peptide



Urcosimod Phase 2 DED Trial

Phase 2 Randomized, Placebo-Controlled DED Trial


- **Enrollment:** 240 randomized subjects / ~80 per study arm
- **Treatment arms:** 3 (Placebo, OK-101 0.05%, OK-101 0.1%)
- **Study duration:** 85 days (~12 weeks) with 6 scheduled patient visits
- **Clinical sites:** Multicenter (U.S.)

Endpoints

- **Primary (through Day 85):** Inferior Corneal Staining (sign); Ocular Discomfort Score (symptom)
- **Secondary:** Total Conjunctival Staining (sign), Tear Film Break-up Time (TFBUT) (sign), Blurred Vision, Pain, Burning/Stinging, Daily Symptom Diary

Urcosimod Demonstrated Significant Pain Relief in Phase 2 DED Trial

Data shown is change from baseline in Intent-To-Treat Population
P values are vs placebo based on Wilcoxon rank sum test



No Severe Adverse Events Demonstrated in Phase 2 DED Study (240 Subjects)

Category	OK-101 (0.1%) (N = 80)	OK-101 (0.05%) (N = 81)	Placebo (N = 79)
Number of Ocular AEs	7	19	7
Number of Ocular TEAEs	6	16	6
Number of Ocular SAEs	0	0	0
Number of Ocular TE-SAEs	0	0	0
Number of Subjects Withdrawn Study Drug due to Ocular TEAE: n (%)	0	1 (1.2)	1 (1.3)
Number of Subjects with Ocular TEAEs (Severity)			
Mild: n (%)	5 (6.3)	14 (17.3)	4 (5.1)
Moderate: n (%)	0	1 (1.2)	0
Severe: n (%)	0	0	0
Number of Subjects with Ocular TEAEs by Relationship to Study Drug			
Definitely Related: n (%)	4 (5.0)	8 (9.9)	0
Probably Related: n (%)	0	0	0
Possibly Related: n (%)	0	1 (1.2)	3 (3.8)
Not Related: n (%)	1 (1.3)	6 (7.4)	1 (1.3)

Urcosimod Drop Comfort: 2 Minutes Post-Instillation Study Eye


Drop Comfort	Urcosimod (0.1%) (n=79)	Urcosimod (0.05%) (n=77)	Placebo (n=76)
Mean Score (SD)	2.5 (2.32)	2.3 (2.32)	1.8 (1.73)
Median	2.0	1.0	1.5

Significant Pain Relief Efficacy and Safety Profile Supported Strong Evidence for Clinical Development Rationale in NCP


Abbreviations: AE = Adverse Event; TEAE = Treatment-Emergent Adverse Event; SAE = Serious Adverse Event; TE-SAE = Treatment-Emergent Serious Adverse Event.

Urcosimod Reduced Neuropathic Corneal Pain (NCP) in Mouse Model*

Ciliary Ligation Model* Illustrates Urcosimod's Potential to Reduce Ocular Pain. Ciliary nerve ligation surgery to create the neuropathic corneal pain (NCP) model



Urcosimod Reduced Corneal Pain Response Comparable to Gabapentin*** (GBP)**





Urcosimod: NCP Clinical Development Plan

Urcosimod Phase 2a NCP Trial Design

ENDPOINTS

Primary Endpoint

(through 12 weeks)


Pain (Visual Analog Scale)

Secondary Endpoint

Ocular Pain by OPAS scores
QoL improvement by OPAS
Drop comfort

Exploratory Endpoints

Change in corneal sensation
Change in corneal nerve density and length
Presence or absence of microneuromas



Urcosimod (0.05%) n = 6

Urcosimod (0.1%) n = 5

Placebo n = 6

Study Overview

Total Subjects: Enrolled = 18
Screen Failures = 6
Randomized Subjects = 18


Baseline characteristics were balanced amongst treatment groups
No drug-related SAEs, most AEs were mild stinging & burning
1 discontinuation due to medical reason unrelated to drug in 0.1% urcosimod group

Phase 2a NCP Clinical Trial Demonstrated Promising Drug Effect

Phase 2a, Randomized, Double Masked, Placebo-Controlled Study Assessing Safety and Efficacy for Urcosimod in Subjects with NCP

STUDY RESULTS

- After 12 weeks of treatment, 75% of per-protocol patients receiving urcosimod (0.05%) showed greater than 80% reduction in neuropathic corneal pain, as measured by VAS, demonstrating highly effective treatment
- Urcosimod (0.05%) demonstrated a mean change from baseline in pain scores as early as Week 4, with sustained efficacy maintained throughout the trial
- Notably, all these responders entered the study with moderate to severe NCP pain scores despite prior use of maximum medical therapy



Urcosimod (0.05%) group showed a mean pain score improvement of **5.5 points** on a 10-point VAS, compared with a mean improvement of 2.75 points for placebo

Urcosimod (0.05%) Signals Promising Nerve Growth Potential

Favorable impact of urcosimod (0.05%) on corneal nerve health, demonstrating corneal nerve restoration


- Median increases in total nerve fiber count vs. placebo
 - (+2.0, n/0.16 mm², IQR 0.54 to 3.63) vs. placebo (−1.92, n/0.16 mm², IQR −2.79 to −0.04)
- Median increases in total nerve fiber length vs. placebo
 - (+2.6 mm/mm², IQR 1.55 to 5.67; p = 0.057) vs. placebo (−1.63 mm/mm², IQR −3.76 to 0.63)

Consistent anatomical improvements support **corneal nerve restoration** and **first-in-class** potential

FDA Endorsed Urcosimod Phase 2b/3 NCP Trial

Phase 2b/3 Randomized, Double-Masked, Placebo-Controlled Study of Urcosimod in NCP	→ Planned enrollment: ~150 subjects → Treatment arms: 3 (Placebo, Urcosimod 0.025%, Urcosimod 0.05%) → Subjects per arm: 50 → Treatment duration: 12 weeks → Visits: 5 scheduled visits → Clinical sites: 6-8 centers
--	---

- FDA confirmed:
- Primary endpoint of the Visual Analogue Scale (VAS) pain reduction
 - ≥ 2 -point improvement on the VAS scale represents a meaningful treatment effect



Neuropathic Corneal Pain (NCP) Development Plan

2024

- ☒ IND Cleared by FDA for OK-101 to Treat NCP
- ☒ Phase 2 Randomized, Placebo-Controlled 48-Patient Trial Initiated to treat NCP

2025

- ☒ Closed Trial to Accelerate Clinical Development
- ☒ Phase 2 Favorable NCP Topline Readout
- ☒ FDA grants Fast Track Designation for NCP

2026+


- ☒ FDA Type C Meeting
- ☐ Initiate Phase 2b/3 Multiple-Dose Study
- ☐ Complete enrollment in Phase 2b/3 (~150 subjects)
- ☐ Phase 2b/3 topline data readout

Fast-Tracking a Potential Therapy for NCP Patients with High Unmet Needs




CLINICAL EVIDENCE

- Phase 2 Proof of Concept trial to treat NCP clearly demonstrated a promising drug effect
- 5.5-point improvement on a 10-point VAS
- 75% of treated patients achieved >80% pain improvement



UNMET NEED

- No FDA-approved treatment available for neuropathic corneal pain (NCP)
- Opportunity for first in class first line therapy with positive reimbursement



NEAR TERM MILESTONES

- FDA confirmed alignment on development strategy
- Initiate Phase 2b/3 trial (2Q26)
- Phase 2b/3 trial fully enrolled (4Q26)
- Topline data (1H27)



APPENDIX